Predictors of loss of residual renal function among new dialysis XXXX .

@entity1 @entity712 @entity6 @entity177 @entity460 @entity454
@entity177 ( @entity177 ) in @entity454 is clinically important as it contributes to adequacy of dialysis, quality of life, and mortality. This study was conducted to determine the predictors of @entity177 in a national random sample of @entity1 initiating hemodialysis and peritoneal dialysis. The study controlled for baseline variables and included major predictors. The end point was loss of @entity177 , defined as a urine volume <200 ml/24 h at approximately 1 yr of follow-up. The adjusted odds ratios (AOR) and P values associated with each of the demographic, clinical, laboratory, and treatment parameters were estimated using an "adjusted" univariate analysis. Significant variables (P < 0.05) were included in a multivariate logistic regression model. Predictors of @entity177 were female gender (AOR = 1.45; P < 0.001), non-white race (AOR = 1.57; P = <0.001), prior history of @entity6 (AOR = 1.82; P = 0.006), prior history of @entity712 (AOR = 1.32; P = 0.03), and time to follow-up (AOR = 1.06 per month; P = 0.03). @entity1 treated with peritoneal dialysis had a 65% lower risk of @entity177 than those on hemodialysis (AOR = 0.35; P < 0.001). Higher serum @entity460 (AOR = 0.81 per mg/dl; P = 0.05), use of an angiotensin-converting enzyme inhibitor (AOR = 0.68; P < 0.001). and use of a @entity460 channel blocker (AOR = 0.77; P = 0.01) were independently associated with decreased risk of @entity177 . The observations of demographic groups at risk and potentially modifiable factors and therapies have generated testable hypotheses regarding therapies that may preserve @entity177 among @entity454 @entity1 .
